Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

A survey of exposure to the use of Xiaflex for the treatment of Peyronie’s disease among United States urology residency programs

International Journal of Impotence Research volume 36, pages 155–159 (2024)Cite this article

Subjects

Abstract

Xiaflex® (collagenase clostridium histolyticum) is a Food and Drug Administration-approved treatment for patients with Peyronie’s disease. Despite its approval and implementation, there is concern that urologists in training are offered minimal exposure to its use. Thus, the purpose of this study was to evaluate the exposure of urology residents to Peyronie’s disease and its management, particularly Xiaflex®. A Google Forms survey regarding the exposure of residents to Peyronie’s disease and use of Xiaflex® was created and disseminated through email to urology programs. Overall, 47 institutional responses were received. At 45 institutions (95.7%), residents receive training in directly evaluating and caring for patients with Peyronie’s disease. At 46 institutions (97.9%), residents receive training in observing and/or performing surgical procedures for Peyronie’s disease. Residents at 31 institutions (66.0%) receive observational or procedural training for non-surgical management of Peyronie’s disease, specifically Xiaflex®. Residents receive non-surgical training from an academic faculty who is fellowship trained in sexual medicine at 25 institutions and an academic faculty not trained in sexual medicine at six institutions. There exists a glaring disparity in residency exposure to Xiaflex®. Further research is warranted to elucidate how programs can provide residents with further exposure to the use of Xiaflex® in patients with Peyronie’s disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Survey Questions.
Fig. 2: State Distribution of Xiaflex® Responses.
Fig. 3: AUA section distribution of Xiaflex® survey responses.
Fig. 4: Residency exposure to the treatment of Peyronie’s Disease.
Fig. 5: Who do residents receive training from?

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are included in this published article.

References

  1. Paulis G, Romano G, Paulis A. Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie’s disease: a retrospective analysis of 309 cases. Res Rep. Urol. 2016;8:95–103.

    PubMed  PubMed Central  Google Scholar 

  2. Smith JF, Walsh TJ, Conti SL, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie’s disease. J Sex Med. 2008;5:2179–84. https://doi.org/10.1111/j.1743-6109.2008.00949.x.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie’s disease in the United States: a population-based study. PLoS One. 2016;11:e0150157. https://doi.org/10.1371/journal.pone.0150157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chung E, Gillman M, Rushton D, Love C, Katz D. Prevalence of penile curvature: a population-based cross-sectional study in metropolitan and rural cities in Australia. BJU Int. 2018;122:42–49. https://doi.org/10.1111/bju.14605.

    Article  PubMed  Google Scholar 

  5. Nguyen HM, Hellstrom WJ, Alzweri L, Chung A, Virasoro R, Tapscott A, et al. 108 Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with peyronie’s Disease: the results of a multi-institutional analysis. J Sex Med. 2019;16:S55–6.

    Article  Google Scholar 

  6. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    Article  CAS  PubMed  Google Scholar 

  7. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. J Urol. 1985;134:280–3.

    Article  CAS  PubMed  Google Scholar 

  8. Nehra A, Alterowitz R, Culkin DJ, Faraday M, Hakim L, Heidelbaugh J, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194:745–53. https://doi.org/10.1016/j.juro.2015.05.098.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Trost L, Huang H, Han X, Burudpakdee C, Hu Y. Treatment patterns and healthcare outcomes with collagenase clostridium histolyticum vs surgery in Peyronie’s disease: a retrospective claims database analysis. Sex Med. 2021;9:100321. https://doi.org/10.1016/j.esxm.2021.100321.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Moghalu OI, Das R, Horns J, Campbell A, Hotaling JM, Pastuszak AW. Trends in treatment of Peyronie’s disease in adult men in the United States from 2008 to 2017—results from an encounter and claims database. Int J Impot Res. 2022;34:280–8. https://doi.org/10.1038/s41443-021-00430-x.

    Article  CAS  PubMed  Google Scholar 

  11. Oberlin DT, Liu JS, Hofer MD, Milose J, Matulewicz RS, Flury SC, et al. An analysis of case logs from American urologists in the treatment of Peyronie’s disease. Urology. 2016;87:205–9. https://doi.org/10.1016/j.urology.2015.08.033.

    Article  PubMed  Google Scholar 

  12. Masterson TA, Nackeeran S, Rainer Q, Hauser N, Marcovich R, Ramasamy R. Survey of microsurgery training availability in US urology residency programs. World J Mens Health. 2021;39:376–80. https://doi.org/10.5534/wjmh.190162.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Montefiore Medical Center, Bronx, NY, USA

    Justin Loloi

  2. Washington State University Elson S. Floyd College of Medicine, Spokane, WA, USA

    Kyle Schuppe

  3. Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA

    Raghuram V. Reddy & Nikhil Kulkarni

  4. Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA

    Farah Rahman, Thomas Masterson & Ranjith Ramasamy

  5. Department of Urology, New York University Langone Health, New York, NY, USA

    Ari Bernstein

  6. Alabama College of Osteopathic Medicine, Dothan, AL, USA

    Pritika Reddy

Authors
  1. Justin Loloi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyle Schuppe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raghuram V. Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farah Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ari Bernstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pritika Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nikhil Kulkarni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Thomas Masterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ranjith Ramasamy
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JL, KS, RVR, FR, AB, PR, NK, TM, and RR prepared the manuscript and figures. All authors approved the submitted manuscript.

Corresponding author

Correspondence to Justin Loloi.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Loloi, J., Schuppe, K., Reddy, R.V. et al. A survey of exposure to the use of Xiaflex for the treatment of Peyronie’s disease among United States urology residency programs. Int J Impot Res 36, 155–159 (2024). https://doi.org/10.1038/s41443-023-00781-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41443-023-00781-7

This article is cited by

Search

Advanced search

Quick links